Skip to main content
博迅生物 logo

博迅生物 — Investor Relations & Filings

Ticker · 920504 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 301 across all filing types
Latest filing 2023-09-21 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920504

About 博迅生物

http://www.boxun.com.cn/

Boxun Medical Biological Instrument Corp. specializes in the development and manufacture of laboratory equipment and medical instruments. The company's core product line includes high-pressure steam sterilizers, constant temperature incubators, CO2 incubators, drying ovens, and environmental test chambers. These instruments are designed for applications in life sciences, healthcare, pharmaceutical research, and environmental monitoring. Boxun focuses on delivering precise thermal control and reliable sterilization solutions, ensuring compliance with international quality standards. Its equipment is utilized in scientific research, clinical diagnostics, and industrial quality control to maintain sterile environments and stable experimental conditions. The company emphasizes technical innovation and product durability to support the requirements of modern laboratory facilities.

Recent filings

Filing Released Lang Actions
2023 年半年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2023 Half-Year Equity Distribution Plan Announcement" and discusses the company's plan to distribute cash dividends based on the 2023 half-year financial results. It references the 2023 half-year report (unaudited) but does not contain the financial report itself. The document includes details about the dividend amount, board and supervisory opinions, and compliance with company bylaws and regulations. It is an announcement regarding the dividend distribution plan rather than the actual financial report or earnings release. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is short (2249 characters), consistent with an announcement rather than a full report.
2023-09-21 Chinese
董事会战略委员会工作细则
Governance Information Classification · 95% confidence The document is a detailed set of rules and procedures for the Board's Strategic Committee of Shanghai BoXun Medical Biological Instruments Co., Ltd. It outlines the committee's composition, responsibilities, meeting rules, and governance structure. There is no financial data, no mention of financial results, no voting results, no announcements of reports, or any other regulatory filings. The content focuses on governance and internal board committee rules, which fits the definition of Governance Information (CGR). The document length is short (1914 characters), and it is not an announcement of a report but the actual governance document itself.
2023-09-21 Chinese
关于公司调整使用部分暂时闲置募集资金进行现金管理额度的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Boxun Medical Biological Instruments Co., Ltd. regarding the adjustment of the usage limit of temporarily idle raised funds for cash management. It details the amount of funds raised, usage status, investment products, risk control measures, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but is a regulatory announcement about the company's capital management activities related to raised funds. It is not a full financial report, earnings release, or management discussion. The document length is 3860 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's fundraising capital usage and cash management adjustments.
2023-09-21 Chinese
国金证券股份有限公司关于上海博迅医疗生物仪器股份有限公司调整使用部分暂时闲置募集资金进行现金管理额度的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guojin Securities Co., Ltd.) regarding the adjustment of the usage of temporarily idle raised funds by Shanghai Boxun Medical Biological Instruments Co., Ltd. It includes specifics about the fundraising, usage, investment products, decision-making process, risk control, and regulatory compliance. The document references regulatory approvals, fundraising details, and board meeting approvals but does not contain financial statements or quarterly/yearly financial results. It is not an announcement of a report but a formal verification opinion related to the use of raised funds. This type of document fits best under the category of Capital/Financing Update (CAP), as it deals with the management and usage of capital raised through equity issuance and related cash management activities.
2023-09-21 Chinese
大华会计师事务所(特殊普通合伙)关于上海博迅医疗生物仪器股份有限公司以自筹资金预先投入募集资金投资项目的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) related to the use of self-raised funds to pre-invest in projects funded by raised capital. It is issued by a certified public accounting firm and includes an audit-like verification opinion on the company's special statement about the pre-investment of self-raised funds. The document contains detailed financial and project investment information as of September 22, 2023. It is not a full annual or interim report but a standalone audit/verification report on a specific financial matter related to capital use and compliance with stock exchange rules. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (6782 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the classification is AR with high confidence.
2023-09-21 Chinese
上海博迅医疗生物仪器股份有限公司超额配售选择权实施结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the implementation results of an over-allotment option (超额配售选择权) related to a public stock issuance by Shanghai Boxun Medical Biological Instruments Co., Ltd. It details the completion of the over-allotment option exercise, changes in share capital, shareholding structure before and after the exercise, and the lock-up periods for shares. It also mentions the involvement of the underwriting securities firm and the issuance of a capital verification report by an accounting firm. The document is a formal announcement of the results of a capital issuance event, specifically the exercise of an over-allotment option, which is a financing activity. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4738 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2023-09-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.